Literature DB >> 16103755

Ethnic differences in the treatment and control of hypertension in patients with diabetes.

Jessica Flynn Riehle1, Daniel T Lackland, Eni C Okonofua, Katherine H Hendrix, Brent M Egan.   

Abstract

Among diabetic hypertensive patients, ethnic differences in blood pressure control and outcomes have been attributed in part to greater reluctance of providers to prescribe combination antihypertensive regimens to African Americans than to Caucasians. African Americans purportedly receive fewer angiotensin-converting enzyme inhibitors (ACEIs) and/or angiotensin receptor blockers (ARBs), which reduce target organ complications. To assess these issues, cross-sectional data were analyzed from 19,864 diabetic hypertensives from 62 primary care clinics. Among diabetic hypertensives, African Americans (N=6230) were less likely than Caucasians (N=8041) to have blood pressure (BP) <130/80 mm Hg at their last clinic visit (23.1% [23.0%-23.2%] vs. 30.7% [30.6%-30.9%]) despite a greater number of prescriptions for antihypertensive medications (2.67 [2.63-2.70] vs. 2.23 [2.20-2.26]). African Americans were more likely than Caucasians to have an ACEI and/or ARB prescribed and to receive prescriptions for at least two antihypertensive medications that included an ACEI or ARB (64.1% [63.8%-64.4%] vs. 53.1% [52.8%-53.4%]). Among diabetic hypertensives, African Americans are less likely than Caucasians to attain BP <130/80 mm Hg, despite receiving more antihypertensive medication prescriptions. African Americans receive more ACEIs and/or ARBs than Caucasians for target organ protection and/or BP control. The data suggest provider prescribing patterns are not a major contributor to ethnic differences in BP control and outcomes in diabetic hypertensives.

Entities:  

Mesh:

Year:  2005        PMID: 16103755      PMCID: PMC8109594          DOI: 10.1111/j.1524-6175.2005.04542.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  28 in total

1.  Ethnic differences in blood pressure control among men at Veterans Affairs clinics and other health care sites.

Authors:  Shakaib U Rehman; Florence N Hutchison; Katharine Hendrix; Eni C Okonofua; Brent M Egan
Journal:  Arch Intern Med       Date:  2005-05-09

2.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.

Authors:  Jackson T Wright; George Bakris; Tom Greene; Larry Y Agodoa; Lawrence J Appel; Jeanne Charleston; DeAnna Cheek; Janice G Douglas-Baltimore; Jennifer Gassman; Richard Glassock; Lee Hebert; Kenneth Jamerson; Julia Lewis; Robert A Phillips; Robert D Toto; John P Middleton; Stephen G Rostand
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

Review 3.  Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.

Authors:  G L Bakris; M Williams; L Dworkin; W J Elliott; M Epstein; R Toto; K Tuttle; J Douglas; W Hsueh; J Sowers
Journal:  Am J Kidney Dis       Date:  2000-09       Impact factor: 8.860

4.  Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes.

Authors:  Sharon H Saydah; Judith Fradkin; Catherine C Cowie
Journal:  JAMA       Date:  2004-01-21       Impact factor: 56.272

5.  Greater impact of coexistence of hypertension and diabetes on silent cerebral infarcts.

Authors:  Kazuo Eguchi; Kazuomi Kario; Kazuyuki Shimada
Journal:  Stroke       Date:  2003-09-18       Impact factor: 7.914

Review 6.  What have we learned from the current trials?

Authors:  Kevin C Abbott; George L Bakris
Journal:  Med Clin North Am       Date:  2004-01       Impact factor: 5.456

7.  Guidelines for hypertension: are quality-assurance measures on target?

Authors:  Gregory M Singer; Munavvar Izhar; Henry R Black
Journal:  Hypertension       Date:  2004-02       Impact factor: 10.190

Review 8.  The importance of blood pressure control in the patient with diabetes.

Authors:  George L Bakris
Journal:  Am J Med       Date:  2004-03-08       Impact factor: 4.965

Review 9.  Definition and epidemiology of hypertensive cardiovascular disease in women: the size of the problem.

Authors:  Stanley S Franklin
Journal:  J Hypertens Suppl       Date:  2002-05

10.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

Authors:  L Hansson; A Zanchetti; S G Carruthers; B Dahlöf; D Elmfeldt; S Julius; J Ménard; K H Rahn; H Wedel; S Westerling
Journal:  Lancet       Date:  1998-06-13       Impact factor: 79.321

View more
  10 in total

1.  Race, ethnicity, and state-by-state geographic variation in hemorrhagic stroke in dialysis patients.

Authors:  James B Wetmore; Milind A Phadnis; Jonathan D Mahnken; Edward F Ellerbeck; Sally K Rigler; Xinhua Zhou; Theresa I Shireman
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-23       Impact factor: 8.237

2.  Impact of race on cumulative exposure to antihypertensive medications in dialysis.

Authors:  James B Wetmore; Jonathan D Mahnken; Sally K Rigler; Edward F Ellerbeck; Purna Mukhopadhyay; Qingjiang Hou; Theresa I Shireman
Journal:  Am J Hypertens       Date:  2012-12-28       Impact factor: 2.689

3.  Impacting population cardiovascular health through a community-based practice network: update on an ASH-supported collaborative.

Authors:  Brent M Egan; Marilyn A Laken; C Shaun Wagner; Sheryl S Mack; Kim Seymour-Edwards; John Dodson; Yumin Zhao; Daniel T Lackland
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-07-11       Impact factor: 3.738

4.  ACE inhibitor and ARB medication use among Medicaid enrollees with diabetes.

Authors:  Claudia M Lora; Alexander W Sokolovsky; Daniel R Touchette; Jing Jin; Xiaojing Hu; Weihua Gao; Ben S Gerber
Journal:  Ethn Dis       Date:  2013       Impact factor: 1.847

5.  High-risk diabetic patients in Medicare Part D programs: are they getting the recommended ACEI/ARB therapy?

Authors:  Yi Yang; Vennela Thumula; Patrick F Pace; Benjamin F Banahan; Noel E Wilkin; William B Lobb
Journal:  J Gen Intern Med       Date:  2010-01-28       Impact factor: 5.128

6.  Cardiovascular risk factor control in communities--update from the ASH Carolinas-Georgia Chapter, the Hypertension Initiative, and the Community Physicians' Network.

Authors:  Brent M Egan; Daniel T Lackland; Priscilla Igho-Pemu; Katharine H Hendrix; Jan Basile; Shakaib U Rehman; Eni C Okonofua; Alexander Quarshie; Adefisayo Oduwole; Anekwe Onwuanyi; James Reed; Chamberlain Obialo; Elizabeth O Ofili
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-12       Impact factor: 3.738

7.  Challenges and risks in attaining the systolic blood pressure goal of <130 mm Hg in all diabetic patients.

Authors:  Brent M Egan
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-01       Impact factor: 3.738

Review 8.  Resistant or difficult-to-treat hypertension.

Authors:  David A Calhoun
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-03       Impact factor: 3.738

9.  Treatment of hypertension and dyslipidemia or their combination among US managed-care patients.

Authors:  Michael P Dutro; Tracey D Gerthoffer; Eric D Peterson; Simon S K Tang; George A Goldberg
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-09       Impact factor: 3.738

10.  Rationale for establishing a mechanism to increase reimbursement to hypertension specialists.

Authors:  William J Elliott; Brent Egan; Thomas D Giles; George L Bakris; William B White; Torry M Sansone
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-04-11       Impact factor: 3.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.